Medindia

X

Stem Cell Product Commercialization Focus of Summit

Wednesday, January 7, 2009 General News J E 4
Advertisement
PHILADELPHIA, Jan. 7 RRY Publications announced that the 4th Annual Stem Cell Summit, the premier gathering of stem cell company executives, scientists and investors, will focus on commercialization of stem cell therapies. The Summit is an intensive one-day event where attendees explore the therapeutic applications of adult and embryonic stem cells, the successful path to stem cell product commercialization, and the latest investment opportunities in this space.



The 4th Annual Stem Cell Summit features 35 corporate presenters, keynote speaker Dr. Arnold Caplan, Ph.D., and a scientific panel discussion. It will take place on February 17, 2009, at Bridgewaters in New York City's historic South Street Seaport.



Confirmed presenting stem cell companies include:



In addition to the company and product overviews, Robin R. Young, CFA, the leading medical technologies analyst in the United States with over 25 years of experience in the cardiovascular, orthopedic and biomaterials industries, will update his 10-year market forecast for the stem cell industry.



"2008 was a record-breaking year for stem cell technologies with three of the largest stem cell transactions ever recorded?one for more than $1 billion for distribution rights, another for $200 million from the U.S. government, and yet another for $85 million to purchase a single stem cell product line," said Young. "It is, therefore, possible that 2009 will be the year that stem cell companies and technologies cross the $100 million annual revenue line and become a billion-dollar-valuation industry."



4th Annual Stem Cell Summit Facts





3DM, Inc. Incell Corporation, LLC Aastrom Biosciences, Inc. MaxCyte, Inc. Aldagen, Inc. Moraga Biotechnology Corporation AllCells, LLC Neuronyx, Inc. Arteriocyte, Inc. Novocell, Inc. ArunA Biomedical, Inc. NuVasive, Inc. BioE Corp. Osiris Therapeutics, Inc. California Stem Cell, Inc. Progenitor Cell Therapy, Inc. Cellerix, S.A. SpineSmith, LP Cognate BioServices, Inc. Stemagen Cytori Therapeutics, Inc. Stematix, Inc. Gamida Cell Ltd. Stemina, Inc. Geron Corp. TiGenix NV Harvest Technologies Corp. Tissue Genesis, Inc. Histogen, Inc. Vet-Stem, Inc. Histogenics Corporation

SOURCE RRY Publications
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Intradigm Closes Final Tranche of $21.4 Million Se...
S
M Resort, Spa and Casino to Include On-Property Ph...